Article Text

Download PDFPDF

Simvastatin modifies the internalization, endocytic trafficking, and the content of ovarian cancer cellderived extracellular microvesicles which are responsible of inducing migration and invasion in vitro
  1. P Mancilla1,
  2. MF Liberona1,
  3. S Kato1,
  4. J Barra2,
  5. A Gonzalez2 and
  6. M Cuello1
  1. 1Department of Gynecology, School of Medicine, Pontificia Universidad Católica de Chile CEBICEM, Santiago Chile
  2. 2Universidad San Sebastián, Santiago Chile


Introduction High grade serous ovarian carcinoma (HGSOC) is the leading cause of death among all gynecological malignancies. Extracellular microvesicles (MVs) are secreted by most cells in the body and play a crucial role regulating cell-to-cell communication and several biological functions. Current evidence shows that MV release and its content are modified in cancer cells compared to normal counterpart. By this mean, cancer cells can condition tumor microenvironment allowing them to metastasize, survive when exposed to adverse conditions (i.e. chemotherapy) and evade immune surveillance. Simvastatin (Simv), a HMGCoA reductase inhibitor and beyond its primary property of reducing cholesterol synthesis, exerts a role in cellular signaling and protein trafficking by inhibiting the isoprenylation of small GTPases. Recently, our group has demonstrated that (Simv) reduces metastasis in HGSOC murine models and improve survival among statin users. Here, our aim was to study the effect of simvastatin in MV release from HGSOC cancer cells, the MV composition, its uptake, its intracellular trafficking in neighbor cancer cells and in the MVinduced migration and metastasis of these cells.

Methods HeyA8-released MVs were isolated upon 24h exposition to Simv (5 µM) or MOCK (DMSO as vehicle) by using differential ultracentrifugation, characterized by transmission electron microscopy (TEM) and immunoblotting (Alix, HSP70, TSG101, and CD63), and quantify by nanoparticle tracking analysis (NTA). For the uptake assays, HeyA8 cells were treated with PKH67-labelled MVs (2,5h) and analyzed by flow cytometry. For MV content composition, proteins involved in adhesion and invasion (i.e. EMMPRIN) were characterized by immunoblotting. The endocytic trafficking was assessed by measuring the colocalization of PKH67-labelled MVs with recycling endosome (Transferrin) and lysosome (Lysotracker) markers by fluorescence microscopy in recipient HeLa cells. For migration and invasion assays HeyA8 cells were incubated with Simv or MOCK-treated MVs for up to 48h.

Results Simv did not modify MV profile and release from HeyA8 cells. However, Simv significantly reduced the EMMPRIN content in MVs and increased its uptake in recipient cancer cells compared with MOCK conditions. Upon Simv exposure, a shift in intracellular trafficking towards recycling endosomes rather than to lysosomes was observed in these cells. More importantly, a significant reduction in migration and invasion induced by MVs in HeyA8 cancer cells was observed upon Simv exposure.

Conclusion Herein, we demonstrated that MVs released by HGSOC cells exert an autocrine and paracrine effect that prompt migration and invasiveness of cancer cells. Among the mechanisms by which Simv inhibit cancer cell metastasis are the modification in MV content, its uptake and intracellular trafficking, all critical steps for determining their pro-carcinogenic effects. Our findings provide preliminary and novel evidence on the relevance of Simv in regulating cell-to-cell communication through MVs and further support for considering the use and maintenance of statins in HGSOC patients. (Research support by Fondecyt 1201083 and 1181907).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.